Join the club for FREE to access the whole archive and other member benefits.

YouthBio Therapeutics unveils its board, with João Pedro de Magalhães as CSO

14-Apr-2022

Key points from article :

YouthBio focuses on developing gene therapies aimed at epigenetic rejuvenation.

Particularly with the help of partial reprogramming by Yamanaka factors.

The company was founded in early 2021 by Yuri Deigin (CEO) and Viet Ly (CFO).

Dr. João Pedro de Magalhães will be the company's CSO.

Dr. Alejandro Ocampo will serve as lead research collaborator.

Previously, Mr. Deigin has led several early-stage pharmaceutical startups.

Deigin is optimistic that "...major breakthroughs that will enable us to add decades of healthy life to people."

Viet Ly is an angel investor and entrepreneur.

"Exploiting cellular reprogramming ... may result in a paradigm shift in medicine," said de Magalhães.

Another company enters the cellular reprogramming race - hopefully at least one will cross the finishing line

Mentioned in this article:

Tap on icon for description, click on resource name for more details.

Academic

Assistant Professor at University of Lausanne.

Academic

Microbiologist at the University of Liverpool studying ageing using computational and experimental approaches.

Company Representative

Co-founder and CFO at YouthBio Therapeutics and General Partner/ Fund Manager at Inception Capital

Company

Developing rejuvenation gene therapies based on partial reprogramming by Yamanaka factors

Company Representative

Co-founder and Director at YouthBio Therapeutics